ReviewFrontiers in immunology2021
Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Article
- Circulating long non-coding RNAs as diagnostic markers of lupus nephritis and 5-year follow-up disease flares.Frontiers in immunology · 2026Article
- Genes causative of primary immunodeficiency are risk factors for and are over-expressed in systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus.Biomarker research · 2025Article
- Precision Medicine in Rheumatology: The Role of Biomarkers in Diagnosis and Treatment Optimization.Journal of clinical medicine · 2025Review
- Cardiovascular autonomic neuropathy is associated with SLEDAI in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Article
- Attribution of psychiatric manifestations to systemic lupus erythematosus in Chinese patients: A retrospective study.World journal of psychiatry · 2025Article
- Changes of Peripheral T Cells in Systemic Lupus Erythematosus Patients.Immunity, inflammation and disease · 2025Article
- Portable Fluorescence Microarray Reader-Enabled Biomarker Panel Detection System for Point-of-Care Diagnosis of Lupus Nephritis.Micromachines · 2025Article
- A serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis.Frontiers in immunology · 2025Article
- Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis.Diagnostics (Basel, Switzerland) · 2024Article
- Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares.Journal of translational autoimmunity · 2024Article
- Systemic mechanisms of necrotic cell debris clearance.Cell death & disease · 2024Review
- Advancing Point-of-Care Diagnosis: Digitalizing Combinatorial Biomarker Signals for Lupus Nephritis.Biosensors · 2024Article
- Exploring the ROS reduction strategies in chronic lupus management.Frontiers in immunology · 2024Article
- Urinary biomarkers associated with podocyte injury in lupus nephritis.Frontiers in pharmacology · 2024Review
- MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy.Clinical and experimental medicine · 2023Review
- Long Non-Coding RNA TUG1 Gene Polymorphism and TUG1 Expression Level as Molecular Biomarkers of Systemic Lupus Erythematosus and Lupus Nephritis.Non-coding RNA · 2023Article
- V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease which can affect various tissues and organs, posing significant challenges for clinical diagnosis and treatment. The etiology of SLE is highly complex with contributions from environmental factors, stochastic factors as well as genetic susceptibility. The current criteria for diagnosing SLE is based primarily on a combination of clinical presentations and traditional lab testing. However, these tests have suboptimal sensitivity and specificity. They are unable to indicate disease cause or guide physicians in decision-making for treatment. Therefore, there is an urgent need to develop a more accurate and robust tool for effective clinical management and drug development in lupus patients. It is fortunate that the emerging Omics have empowered scientists in the discovery and identification of potential novel biomarkers of SLE, especially the markers from blood, urine, cerebrospinal fluids (CSF), and other bodily fluids. However, many of these markers have not been carefully validated for clinical use. In addition, it is apparent that individual biomarkers lack sensitivity or specificity. This review summarizes the sensitivity, specificity and diagnostic value of emerging biomarkers from recent studies, and discusses the potential of these markers in the development of biomarker panel based diagnostics or disease monitoring system in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.